

Networking Activities Pillar and HITRI*plus* Seminars

22-23.05.2024

Manjit Dosanjh (Pillar Coordinator)



Global Objectives for Networking Pillar

- To promote and communicate outcome of research activities among all HITRIplus partners
- To catalyse the collaboration between the different scientific communities (oncologists, physicists, radiobiologists, biomedical engineers.....), necessary for successful development and improvements in hadron therapy at the project and European level
- To promote hadron-therapy to the research community all over Europe and beyond
- To increase the awareness of HT to general public and the research and medical communities
- To highlight new possibility for cancer patients of this treatment
- To promote transnational access and access to beam time from HITRIplus
- To develop training courses for student, personnel working at the facilities and training of "end-users" (researchers that want to use the facility)



22/05/2024



Networking Activities: WP2-WP5 Coordinators

- WP2: Communication and Networking: Peter Gruebling, SEEIIST
- WP3: Clinical Networking: Piero Fossati, MedAustron
- WP4: Innovation, Technology, Industry: Manuela Cirilli, CERN
- WP5: Education and Training: Nicholas Sammut, Uni of Malta









22/05/2024

Peter Gruebling, SEEIIST MedAustron Manuela Cirilli, CERN ammut, Uni of Malta





WP2 Deliverables and Milestones

Deliverable Title	WP number	r ⁹ Lead beneficiary	Тур	e ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷
Dissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through out	WP2	1 - CNAO	Repo	ort	Public	3
Dissemination and outreach activities developed and regularly updated	WP2	13 - SEEIIST	Repo	ort	Public	42
Provide an annual activity report for the NA Pillar and final scientific achievements including the use and dissemination of foreground.	WP2 13 - SEEIIST		Repo	ort	Public	46
Milestone title	I	ead beneficiary.	D	ate (in	Means of verifica	tion
Project website launched	1 1	- CNAO	2		Realization of Proj	ect Website
	Deliverable Title Dissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through out Dissemination and outreach activities developed and regularly updated Provide an annual activity report for the NA Pillar and final scientific achievements including the use and dissemination of foreground. Milestone title	Deliverable TitlenumberDissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through outWP2Dissemination and outreach activities developed and regularly updatedWP2Provide an annual activity report for the NA Pillar and final scientific achievements including the use and dissemination of foreground.WP2Milestone titleI	Deliverable Titlenumber?Lead beneficiaryDissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through outWP21 - CNAODissemination and outreach activities developed and regularly updatedWP213 - SEEIISTProvide an annual activity report for the NA Pillar and final scientific achievements including the use 	Deliverable Titlenumber?Lead beneficiaryTypeDissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through outWP21 - CNAORepoDissemination and outreach activities developed and regularly updatedWP213 - SEEIISTRepoProvide an annual activity report for the NA Pillar and final scientific achievements including the use and dissemination of foreground.WP213 - SEEIISTRepoMilestone titleLead beneficiaryD D m	Deliverable Titlenumber9Lead beneficiaryType15Dissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through outWP21 - CNAOReportDissemination and outreach activities developed and regularly updatedWP213 - SEEIISTReportProvide an annual activity report for the NA Pillar and final scientific achievements including the use and dissemination of foreground.WP213 - SEEIISTDue Date (in months)Milestone titleLead beneficiaryDue Date (in months)Due Date (in months)	Deliverable Title number ^o Lead beneficiary Type ¹⁵ level ¹⁶ Dissemination to the community about the possibility of the TA and access to clinical research with patients from EU - through out WP2 1 - CNAO Report Public Dissemination and outreach activities developed and regularly updated WP2 13 - SEEIIST Report Public Provide an annual activity report for the NA Pillar and final scientific achievements including the use and dissemination of foreground. WP2 13 - SEEIIST Report Public Milestone title Lead beneficiary Due Date (in months) Means of verifica





done done and in progress done and in progress



THE IMPACT OF DEDICATED COMMUNICATION

Raise Awareness, Build Communities, Promote Collaboration in Multidisciplinary field of Particle Therapy

Highlighting how HITRI*plus* project is doing this by providing opportunities in all aspects from fundamental research to clinics and sharing this with wider community and encouraging them to join.

64 mm - 100





Quer ber samt Bill

receiverstory status and paragoy facility warring excernant of a hadronthanapy facility warring the awating and Scientific day on SNUT

and an other states and a second second

Columnia in the Register spins is the Lineary of

No. Statistical Additional Conference (Security English and Security English), and Security English and Securit

- Applications with Engine providence in colored framework, making a providence (logicizing considering to colored framework)
- A DESCRIPTION OF A DESC
- Street Martin Control Toronto, Street Adaptive Street Stre

Name of Concession, Name and Address of Concession, Name of Conces

and the second s



HETTOPTICS Herestern

All Summers

The Reality Is the last, for the presence is presented to the last spectrum of the data of the data barriers is used that the conclusion is the last spectrum distance that the data barriers is used to be the spectrum of the last spectrum spectrum of the spectrum distances and a spectrum distance that the spectrum of the spin distances and the spectrum distance the spectrum spectrum of the spin distances and the spectrum distance the spectrum spectrum of the spin distances and the spectrum distances are as the spectrum of the spin distances and the spectrum distances are as the spectrum of the spin distances and the spectrum distances are as the spectrum of the spin distances and the spectrum distances are as the spectrum of the spin distances are as the spectrum distances are as the spectrum of the spin distances are as the spectrum distances are as the spectrum of the spin distances are as the spectrum distances are as the spectrum of the spin distances are as the spectrum distances are as the spin distance are as the spectrum of the spin distances are as the spin distance are as the spin distance are as the spectrum of the spin distances are as the spin distance are as the spin distan

No. of Concession, Name



ing Hadronthempy longhts and timovati

A solution of the second secon



Haris and concess summaries of some of the numerous key presentations from the recent evition showcase the transmitted innovation and industrialities in their respective balance.

Name and Address of the Owner, where

WP3: CLINICAL NETWORKING

WP3: Clinical networking

WP NA3	Start Date	Month 1		End Date	Mon	Month 48	
WP Title:	Clinical Net	working					
Participant no.							
Participant	MEDA	HIT	CNA	O MI	Т		
Person months	19	25	33	17	7		
Objectives							
 Task 3.1: Trial design for innovativ Review preclinical data to i Design one trial as a templa Task 3.2: European registry of heav Set up a European registry f Task 3.3: European agreement for O Review existing data on OA Perform pooled data analys 	dentify promis ite for bringing y ion therapy p to collect data DARs dose const ARs dose const	sing novel appr g innovative he patients on rare cancers istraints with h	avy ion th s treated w eavy ion t the clinic	erapy approad with heavy ion herapy al facilities	ches ii	n the clinic	-

Task 3.1

Hypoxia and reoxygenation Synergistic effect of CIRT and immunotherapy LET based optimization





Task 3.2

1										Previous car	ncer	
Patient ID	Sex Date of birth	h Age	Type of diagn	osis Comorbidity	Previous cancer	Specify cancer	Year of diagnosis	Radiotherapy treatmen	Year of radiotherapy	Specify energy	Total dose Chemotherapy treatm	nent? Year
	- Relapsed T	Tumor Tumor Tumor Tumor	r - Local (T) r - Regional (N) r - Metastatic (M)		- Yes - No - Unknown			Campo Chiara: - Yes - No - Unknown	Campo - Carbon - Protons - Photon - Unkonv	s Is	- Yes - No - Unknown	
				po Chiara: rding to MedDRA								
	·				/		_					





The database has so far been used only by CNAO

In the last phase of the project the database will be used to support the activity of task 3.3.



22/05/2024



WP3: Deliverables and Milestones

Deliverable Number ¹⁴	Deliverable Title	WP number ⁹	Lead beneficiary	Type ¹⁵	Dissemination level ¹⁶	Due Date (in months) ¹⁷	Milestone number ¹⁸	Milestone title	Lead beneficiary	Due Date (in months)	Means of verification
	Review of promising innovative heavy ion therapy approaches to						MS3	Evaluation of impact on European centres OARs constraints	10 - MEDA	42	Report on the evaluation of Organ at Risk constraints on the European centres
D3.1	be brought to the clinics and Trial protocol for innovative heavy ion therapy concept	WP3	10 - MEDA	Report	Public	18	MS14	Evaluation of web based registry development status	10 - MEDA	18	Report on the development status of the web based registry
D3.2	Web based heavy ion therapy patient registry	WP3	1 - CNAO	Websites, patents filling, etc.	Confidential, only for memb of the consortin (including the Commission Services)			MedA	ustron		
D3.3	Dose constraints of OARs in use at European heavy ion therapy facilities and Recommendations for dose constraints on one OAR based on pooled data analysis	WP3	8 - UKHD	Report	Public			JAO for Oncological Hadrontherapy		🔊 KLII	VERSITÄTS NIKUM DELBERG
D3.4	Trial protocol for innovative heavy ion therapy concept	WP3	10 - MEDA	Report	Public						














WP4: Deliverables and Milestones

Deliverable Number ¹⁴	Deliverable Title	Lea	ad beneficiary	Type ¹⁵		Di	ssemination le
D4.1	HITRIplus technologies and dissemination plan	4 -	CERN	Report	t		onfidential, only members of the nsortium (inclue Commission rvices)
D4.2	Value propositions	7 -	GSI	Report		Public	
D4.3	Technology matching event	9 -	INFN	Report		Pu	blic
Milestone number ¹⁸	Milestone title		Lead beneficiary		Due Date mont		Means of ver
MS4	First meeting of the Technology Overview committee		4 - CERN		8		Meeting of th Overview cor dedicated to the workplan.







Results so far

- <u>12</u> HITRIPLUS Technologies Identified
- <u>3</u> Companies have signed the Memorandum of Understanding with the coordinator
- <u>19</u> Companies have expressed industrial interest
- <u>7</u> Value Propositions and <u>one</u> brochure for WP7-12 technologies have been produced targeting companies

- social media
- Legal Framework)



22/05/2024

Ongoing activities

 Communication and awareness of the HITRIPLUS technologies targeting companies on website and

• Active outreach to companies at conferences (PTCOG, and possibly ESTRO)

Advising on usage of Technology Transfer Tools (e.g.



WP5: Deliverables and Milestones

Task	Deliverable	Lead	Due Date	% Completed	Status
5.1	Delivery of Specialised Training Courses	SEEIIST	M30	100%	Completed Deliverable submitted
5.2	Delivery of Masterclasses and train-the-trainer masterclasses	GSI	M47	95%	Completed Report in Progress
5.3	Provision of e-learning courses	UM	M30	100%	Completed Deliverable submitted
5.4	Organisation of secondments and internships: calendar of events	UM	M24	100%	Completed Deliverable submitted

M5.1	Specialised Courses and Masterclass Definition	SEEIIST	M18	100%	Completed Deliverable Submitted
------	--	---------	-----	------	------------------------------------









22/05/2024





Networking Pillar - HITRIplus Seminars

Manjit Dosanjh



22/05/2024



HITRIplus Seminars Overview

HITRI*plus* Monthly Seminars, organized by the Networking Pillar Coordinator, convene multidisciplinary experts to advance heavy ion therapy research, showcasing the latest developments and fostering global collaboration. Popular and well attended

With 17 seminars held to date, featuring prominent speakers like Dr. Noriyuki Okonogi and Prof. Aswin Hoffmann, these sessions have highlighted innovations such as Immuno-CIRT, FLASH radiotherapy, and MRI-guided proton therapy

Recorded seminars are accessible via the HITRI*plus* website and YouTube channel, ensuring widespread dissemination and ongoing educational opportunities.





STEADY PROGRESS: CONSISTENT SEMINAR SUCCESS AND ATTENDANCE SINCE OUR LAST MEETING



FRANCESCA ALBERTINI

SCIENTIFIC COORDINATOR, PSI



MANJIT DOSANJH

PROJECT LEADER, STELLA PRO



PAWEL MOSKAL



PROFESSOR, **JAGIELLONIAN** UNIVERSITY (JU)



ASWIN L. HOFFMANN

HEAD OF EXPERIMENTAL **MR-PROTON THERAPY AT** ONCORAY (DRESDEN)




LAURA VALLOW

PROFESSOR OF RADIATIO ONCOLOGY AND THE DEP CHAIR FOR THE DEPARTM **RADIATION ONCOLOGY A CLINIC FLORIDA**

https://www.hitriplus.eu/hitri pl us news/hitriplus-seminars/

https://www.hitriplus.eu/hitri_plus_news/hitriplus-seminars/





uropean Union's Horizon 2020 rant agreement No 101008548

Thank you and happy to answer your questions



